Objectives. Estramustine and etoposide have been shown to inhibit the
growth of prostate cancer cells in experimental models. An in vivo syn
ergism of the two agents, when administered to patients with metastati
c prostate cancer refractory to hormone therapy, has been reported, To
confirm these results, we administered this combination to a large nu
mber of patients with hormone-refractory prostate cancer (HRPC). Metho
ds. Fifty-six patients with metastatic HRPC were treated with oral est
ramustine 140 mg three times a day and oral etoposide 50 mg/m(2)/day f
or 21 days. Therapy was discontinued for 7 days and the cycle was then
repeated. Therapy was continued until evidence of disease progression
or unacceptable toxicity occurred. To control for the possible interf
erence of an antiandrogen withdrawal effect, all patients discontinued
antiandrogen therapy and were not enrolled in the study unless there
was evidence of disease progression. Results. Forty-five percent of 33
patients with measurable soft tissue disease demonstrated an objectiv
e response, which included five complete and ten partial responses, Am
ong 52 patients with osseous disease, 17% showed improvement and 50% s
howed stability of bone scan, Thirty patients (58%) demonstrated a dec
rease of more than 50% in pretreatment prostate-specific antigen (PSA)
levels, The median survival of all patients was 13 months. Good pretr
eatment performance status, measurable disease response, improvement o
r stability of bone scan, and PSA response were important predictors o
f longer survival. Conclusions. We conclude that the combination of es
tramustine and etoposide is an active and well-tolerated oral regimen
in HRPC. (C) 1997, Elsevier Science Inc. All rights reserved.